Royalty Pharma (RPRX)
(Delayed Data from NSDQ)
$37.91 USD
+0.03 (0.08%)
Updated Aug 5, 2025 04:00 PM ET
After-Market: $37.92 +0.01 (0.03%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth F Momentum C VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
RPRX 37.91 +0.03(0.08%)
Will RPRX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for RPRX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for RPRX
Countdown to Royalty Pharma (RPRX) Q2 Earnings: A Look at Estimates Beyond Revenue and EPS
Royalty Pharma (RPRX) Earnings Expected to Grow: Should You Buy?
RPRX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Should You Invest in the iShares U.S. Pharmaceuticals ETF (IHE)?
Royalty Pharma (RPRX) Reports Q1 Earnings: What Key Metrics Have to Say
Royalty Pharma (RPRX) Surpasses Q1 Earnings and Revenue Estimates
Other News for RPRX
Earnings Scheduled For August 6, 2025
Royalty Pharma Q2 2025 Earnings Preview
Here are the major earnings before the open Wednesday
Fidelity Dividend Growth Fund Q2 2025 Commentary
RPRX: Citigroup Raises Price Target for Royalty Pharma | RPRX Stock News